Cardiff Oncology Statistics

Total Valuation

FRA:XE7C has a market cap or net worth of EUR 125.74 million. The enterprise value is 74.49 million.

Market Cap	125.74M
Enterprise Value	74.49M

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	67.36M
Shares Outstanding	n/a
Shares Change (YoY)	+40.37%
Shares Change (QoQ)	+0.53%
Owned by Insiders (%)	2.42%
Owned by Institutions (%)	37.71%
Float	65.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	294.47
PB Ratio	3.02
P/TBV Ratio	3.02
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.73
EV / Sales	172.84
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.07

Financial Position

The company has a current ratio of 4.20, with a Debt / Equity ratio of 0.02.

Current Ratio	4.20
Quick Ratio	4.14
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -102.71% and return on invested capital (ROIC) is -66.55%.

Return on Equity (ROE)	-102.71%
Return on Assets (ROA)	-52.99%
Return on Invested Capital (ROIC)	-66.55%
Return on Capital Employed (ROCE)	-109.44%
Revenue Per Employee	12,939
Profits Per Employee	-1.30M
Employee Count	33
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -18.49% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-18.49%
50-Day Moving Average	1.82
200-Day Moving Average	2.51
Relative Strength Index (RSI)	53.88
Average Volume (20 Days)	300

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	17.50

Income Statement

In the last 12 months, FRA:XE7C had revenue of EUR 427,002 and -43.00 million in losses. Loss per share was -0.68.

Revenue	427,002
Gross Profit	-33.64M
Operating Income	-45.77M
Pretax Income	-42.97M
Net Income	-43.00M
EBITDA	-45.46M
EBIT	-45.77M
Loss Per Share	-0.68

Full Income Statement

Balance Sheet

The company has 51.64 million in cash and 860,823 in debt, giving a net cash position of 50.78 million.

Cash & Cash Equivalents	51.64M
Total Debt	860,823
Net Cash	50.78M
Net Cash Per Share	n/a
Equity (Book Value)	41.58M
Book Value Per Share	0.62
Working Capital	40.14M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -35.99 million and capital expenditures -37,501, giving a free cash flow of -36.02 million.

Operating Cash Flow	-35.99M
Capital Expenditures	-37,501
Free Cash Flow	-36.02M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-10,719.57%
Pretax Margin	-10,064.28%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:XE7C does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-40.37%
Shareholder Yield	-40.37%
Earnings Yield	-34.19%
FCF Yield	-28.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 20, 2019. It was a reverse split with a ratio of 0.1666666667.

Last Split Date	Feb 20, 2019
Split Type	Reverse
Split Ratio	0.1666666667

Scores

FRA:XE7C has an Altman Z-Score of -3.02 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.02
Piotroski F-Score	1